JLE

Epileptic Disorders

MENU

Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs Volume 16, numéro 4, December 2014

  • [Aguglia et al., 2009] Aguglia U., Barboni G., Battino D. Italian consensus conference on epilepsy and pregnancy, labor and puerperium. Epilepsia. 2009;50:7-23. Suppl. 1
  • [Akamine et al., 2012] Akamine Y., Miura M., Yasui-Furukori N. Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers. Br J Clin Pharmacol. 2012;73:478-481.
  • [Andersen et al., 1991] Andersen B.B., Mikkelsen M., Vesterager A. No influence of the antidepressant paroxetine on carbamazepine valproate and phenytoin. Epilepsy Res. 1991;10:201-204.
  • [Anderson et al., 1996] Anderson G.D., Yau M.K., Gidal B.E. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther. 1996;60:145-156.
  • [Barcs et al., 2000] Barcs G., Walker E.B., Elger C.E. Oxcarbazepine placebo controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia. 2000;41:1597-1607.
  • [Battino et al., 1995] Battino D., Estienne M., Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Clin Pharmacokinet. 1995;29:257-286.
  • [Bertschy et al., 1990] Bertschy G., Vandel S., Jounet J.M. Valpromide-amitriptyline interaction: Increase in the bioavailability of amitriptyline and nortriptyline caused by valpromide. Encephale. 1990;16:43-45.
  • [Besag et al., 1998] Besag F.M., Berry D.J., Pool F. Carbamazepine toxicity with lamotrigine: Pharmacokinetic or pharmacodynamic interaction?. Epilepsia. 1998;39:183-187.
  • [Bialer et al., 2004] Bialer M., Doose D.R., Murthy B. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet. 2004;12:763-780.
  • [Birbeck et al., 2012] Birbeck G.L., Clifford D.B., Fraimow H. Antiepileptic drug selection for people with HIV/AIDS: Evidence-based guidelines from the ILAE and AAN. Epilepsia. 2012;53:207-214.
  • [Botts et al., 2008] Botts S., Diaz F.J., Santoro V. Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. Progr Neuro-Psychopharmacol Biol Psychiatry. 2008;32:1453-1458.
  • [Breckenridge, 1974] Breckenridge A. Drug interactions with oral anticoagulants. BMJ. 1974;2:397-400.
  • [Brodie et al., 2009] Brodie M.J., Rosenfeld W.E., Vazquez B. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: A randomized placebo-controlled trial. Epilepsia. 2009;50:1899-1909.
  • [Brodie et al., 2013] Brodie M.J., Mintzer S., Pack A.M. Enzyme induction with antiepileptic drugs: Cause for concern?. Epilepsia. 2013;54:11-27.
  • [Brosen and Kragh-Sorensen, 1993] Brosen K., Kragh-Sorensen P. Concomitant intake of nortriptyline and carbamazepine. Ther Drug Monit. 1993;15:258-260.
  • [Burger et al., 2008] Burger D.M., Huisman A., Van Ewijk N. The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe. Clin Pharmacol Ther. 2008;84:698-703.
  • [Canger et al., 1990] Canger R., Altamura A.C., Belvedere O. Conventional vs controlled-release carbamazepine: A multicentre, double-blind, cross-over study. Acta Neurol Scand. 1990;82:9-13.
  • [Capewell et al., 1988] Capewell S., Freestone S., Critchley J.A. Reduced felodipine bioavailability in patients taking anticonvulsants. Lancet. 1988;2:480-482.
  • [Castberg and Spigset, 2007] Castberg I., Spigset O. Effect of comedication on the serum level of aripiprazole: Evidence from a routine therapeutic drug monitoring service. Pharmacopsychiatry. 2007;40:107-110.
  • [Castberg et al., 2007] Castberg I., Skogvoll E., Spigset O. Quetiapine and drug interactions: Evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry. 2007;68:1540-1545.
  • [Centorrino et al., 1994] Centorrino F., Baldessarini R.J., Kando J. Serum concentrations of clozapine and its metabolites: Effects of cotreatment with fluoxetine or valproate. Am J Psychiatry. 1994;151:123-125.
  • [Citrome et al., 2005] Citrome L., Josiassen R., Bark N. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol. 2005;45:89-93.
  • [Citrome et al., 2007] Citrome L., Macher J.P., Salazar D.E. Pharmacokinetics of aripiprazole and concomitant carbamazepine. J Clin Psychopharmacol. 2007;27:279-283.
  • [Chiron, 2007] Chiron C. Stiripentol. Neurotherapeutics. 2007;4:123-125.
  • [Cloyd et al., 2007] Cloyd J.C., Marino S., Birnbaum A.K. Factors affecting antiepileptic drug pharmacokinetics in community-dwelling elderly. Int Rev Neurobiol. 2007;81:201-210.
  • [Cottencin et al., 1995] Cottencin O., Regnaut N., Thévenon-Gignac C. Carbamazepine-fluvoxamine interaction. Consequences for the carbamazepine plasma level (French). Encephale. 1995;21:141-145.
  • [Cropp and Bussey, 1997] Cropp J.S., Bussey H.I. A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy. 1997;17:917-928.
  • [Curry et al., 1970] Curry S.H., Davis J.M., Janowsky D.S. Factors affecting chlorpromazine plasma levels in psychiatric patients. Arch Gen Psychiatry. 1970;22:209-215.
  • [Dawson et al., 1978] Dawson G.W., Brown H.W., Clark B.G. Serum phenytoin after Ethosuximide. Ann Neurol. 1978;4:583-584.
  • [De Jonge et al., 2005] De Jonge M.E., Huitema A.D., van Dam S.M. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin. Cancer Chemother Pharmacol. 2005;55:507-510.
  • [DeToledo et al., 1997] DeToledo J.C., Haddad H., Ramsay R.E. Status epilepticus associated with the combination of valproic acid and clomipramine. Ther Drug Monit. 1997;19:71-73.
  • [De Turck et al., 1998] De Turck B.J., Diltoer M.W., Corneli P.J. Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin. J Antimicrob Chemother. 1998;42:563-564.
  • [Di Cenzo et al., 2004] Di Cenzo R., Peterson D., Cruttenden K. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2004;48:4328-4331.
  • [Ebert et al., 2000] Ebert U., Thong N.Q., Oertel R., Kirch W. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. Eur J Clin Pharmacol. 2000;56:299-304.
  • [Eliquis, 2014] Eliquis. Summary of Product Carachteristics. http://www.medicines.org.uk/emc/medicine/24988/SPC/Eliquis+2.5+mg+film-coated+tablets/#INTERACTIONS (last accessed April 29, 2014).
  • [Eriksson et al., 1996] Eriksson A.S., Hoppu K., Nergårdh A., Boreus L. Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. Epilepsia. 1996;37:769-773.
  • [Facciola et al., 1998] Facciola G., Avenoso A., Spina E., Perucca E. Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia. Ther Drug Monit. 1998;20:628-630.
  • [Fattore and Perucca, 2011] Fattore C., Perucca E. Novel medications for epilepsy. Drugs. 2011;71:2151-2178.
  • [Finley and Warner, 1994] Finley P., Warner D. Potentially impact of valproic acid therapy on clozapine disposition. Biol Psychiatry. 1994;36:487-488.
  • [Flockart and Tanus-Santos, 2002] Flockart D.A., Tanus-Santos J.E. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med. 2002;162:405-412.
  • [Forrest et al., 1970] Forrest F.M., Forrest I.S., Serra M.T. Modifications of chlorpromazine metabolism by some other drugs frequently administered to psychiatric patients. Biol Psychiatry. 1970;2:53-58.
  • [Franco et al., 2013] Franco V., Crema F., Iudice A. Novel treatment options for epilepsy: Focus on perampanel. Pharmacol Res. 2013;70:35-40.
  • [Freitas-Lima et al., 2011] Freitas-Lima P., Alexandre V., Pereira J.R. Influence of enzyme inducing antiepileptic drugs on the pharmacokinetics of levetiracetam in patients with epilepsy. Epilepsy Res. 2011;94:117-120.
  • [Fycompa, 2013] Fycompa. Summary of product characteristics [online]. www.ema.europa.eu/ema/docs/en_GB/document_library/EPASR_-_Product_Infromation/human/002434/WC500130815.pdf (accessed 23 January 2013).
  • [Galimberti et al., 2006] Galimberti C.A., Mazzucchelli I., Arbasino C. Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy. Epilepsia. 2006;47:1569-1572.
  • [Gex-Fabry et al., 2003] Gex-Fabry M., Balant-Gorgia A.E., Balant L.I. Therapeutic drug monitoring of olanzapine: The combined effect of age, gender, smoking, and comedication. Ther Drug Monit. 2003;25:46-53.
  • [Gidal et al., 2003] Gidal B.E., Sheth R., Parnell J. Evaluation of valproic acid dose and concentration effects on lamotrigine pharmacokinetics: Implications for conversion to lamotrigine monotherapy. Epilepsy Res. 2003;57:85-93.
  • [Giessmann et al., 2004] Giessmann T., May K., Modess C. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther. 2004;76:192-200.
  • [Glauser, 2004] Glauser T.A., Shorvon S., Perucca E., Fish D., Dodson E. Ethosuximide. The treatment of epilepsy. Blackwell; 2004391-402. Second Edition
  • [Greenblatt et al., 1987] Greenblatt D.J., Miller L.G., Shader R.I. Clonazepam pharmacokinetics, brain uptake, and receptor interactions. J Clin Psychiatry. 1987;48:4-11. Suppl
  • [Grimm et al., 2006] Grimm S.W., Richtand N.M., Winter H.R. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2006;61:58-69.
  • [Grimsley et al., 1991] Grimsley S.R., Jann M.W., Carter J.G. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther. 1991;50:10-15.
  • [Harder and Thürmann, 1996] Harder S., Thürmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet. 1996;30:416-444.
  • [Haselberger et al., 1997] Haselberger M.B., Freedman L.S., Tolbert S. Elevated serum phenytoin concentrations associated with coadministration of sertraline. J Clin Psychopharmacol. 1997;17:107-109.
  • [Haslemo et al., 2012] Haslemo T., Olsen K., Lunde H., Molden E. Valproic Acid significantly lowers serum concentrations of olanzapine-an interaction effect comparable with smoking. Ther Drug Monit. 2012;34:512-517.
  • [Hassan et al., 2005] Hassan Y., Awaisu A., Aziz N.A., Ismail O. The complexity of achieving anticoagulation control in the face of warfarin-phenytoin interaction: An Asian case report. Pharm World Sci. 2005;27:16-19.
  • [Hellwig et al., 2011] Hellwig T.R., Onisk M.L., Chapman B.A. Potential interaction between valproic acid and doripenem. Curr Drug Saf. 2011;6:54-58.
  • [Henriksen and Johannessen, 1982] Henriksen O., Johannessen S.I. Clinical and pharmacokinetic observations on sodium valproate - a 5-year follow-up study in 100 children with epilepsy. Acta Neurol Scand. 1982;65:504-523.
  • [Hermann et al., 2003] Hermann R., Knebel N.G., Niebch G. Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur J Clin Pharmacol. 2003;58:795-802.
  • [Herzog et al., 2005] Herzog A.G., Farina E.L., Blum A.S. Serum valproate levels with oral contraceptive use. Epilepsia. 2005;46:970-971.
  • [Hirata-Koizumi et al., 2007] Hirata-Koizumi M., Saito M., Miyake S., Hasegawa R. Adverse events caused by drug interactions involving glucuronoconjugates of zidovudine, valproic acid and lamotrigine, and analysis of how such potential events are discussed in package inserts of Japan, UK and USA. J Clin Pharm Ther. 2007;32:177-185.
  • [Kahn et al., 1990] Kahn E.M., Schulz S.C., Perel J.M. Change in haloperidol level due to carbamazepine: A complicating factor in combined medication for schizophrenia. J Clin Psychopharmacol. 1990;10:54-57.
  • [Kanner, 2011] Kanner A.M. Depression and epilepsy: A bidirectional relation?. Epilepsia. 2011;52:21-27. Suppl 1
  • [Kaufman and Gerner, 1998] Kaufman K.R., Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure. 1998;7:163-165.
  • [Kennedy et al., 2013] Kennedy W.K., Jann M.W., Kutscher E.C. Clinically significant drug interactions with atypical antipsychotics. CNS Drugs. 2013;27:1021-1048.
  • [Ketter, 2008] Ketter T.A. Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder. J Clin Psychiatry. 2008;69:9-15. Suppl 5
  • [Kidron et al., 1985] Kidron R., Avrebach I., Klein E. Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. Biol Psychiatry. 1985;20:219-222.
  • [Kim, 2002] Kim R.B. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev. 2002;34:47-54.
  • [Krämer et al., 1992] Krämer G., Tettenborn B., Klosterskov Jensen P. Oxcarbazepine does not affect the anticoagulant activity of warfarin. Epilepsia. 1992;33:1145-1148.
  • [Kulshrestha et al., 1978] Kulshrestha V.K., Thomas M., Wadsworth J., Richens A. Interaction between phenytoin and antacids. Br J Clin Pharmacol. 1978;6:177-179.
  • [Jaeckle et al., 2009] Jaeckle K.A., Ballman K., Furth A., Buckner J.C. Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology. 2009;73:1207-1213.
  • [Jerling et al., 1994] Jerling M., Lindstrom L., Bondesson U., Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service. Ther Drug Monit. 1994;16:368-454.
  • [Ji et al., 2008] Ji P., Damle B., Xie J. Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. J Clin Pharmacol. 2008;48:948-956.
  • [Johannessen and Johannessen Landmark, 2010] Johannessen S.I., Johannessen Landmark C. Antiepileptic drug interactions - Principles and clinical implications. Current Neuropharmacology. 2010;8:254-267.
  • [Johannessen Landmark and Patsalos, 2010] Johannessen Landmark C., Patsalos P.N. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother. 2010;10:119-140.
  • [Johnston and Crawford, 2014] Johnston C.A., Crawford P.M. Anti-epileptic drugs and hormonal treatments. Curr Treat Options Neurol. 2014;16:288.
  • [Joseph and Wroblewsky, 1993] Joseph A.B., Wroblewsky B.A. Potentially toxic serum concentrations of desipramine after discontinuation of valproic acid. Brain Injury. 1993;7:463-465.
  • [Lai et al., 1978] Lai A.A., Levy R.H., Cutler R.E. Time-course of interaction between carbamazepine and clonazepam in normal man. Clin Pharmacol Ther. 1978;24:316-323.
  • [Lane et al., 1998] Lane H.Y., Su K.P., Chang W.H. Elevated plasma clozapine concentrations after phenobarbital discontinuation. J Clin Psychiatry. 1998;59:131-133.
  • [Lazarowski et al., 2007] Lazarowski A., Czornyj L., Lubienieki F. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia. 2007;48:140-149. Suppl 5
  • [Leppik, 2008] Leppik I.E. Treatment of epilepsy in the elderly. Curr Treat Options Neurol. 2008;10:239-245.
  • [Lim et al., 2004] Lim M.L., Min S.S., Eron J.J. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr. 2004;36:1034-1040.
  • [Lim et al., 2004] Lim M.L., Min S.S., Eron J.J. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr. 2004;36:1034-1040.
  • [L’Homme et al., 2006] L’Homme R.F., Dijkema T., van der Ven A.J., Burger D.M. Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. J Acquir Immune Defic Syndr. 2006;43:193-196.
  • [Löscher et al., 2011] Löscher W., Luna-Tortós C., Römermann K., Fedrowitz M. Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected. Curr Pharm Des. 2011;17:2808-2828.
  • [Löscher and Schmidt, 2006] Löscher W., Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia. 2006;47:1253-1284.
  • [Luszczki, 2009] Luszczki J.J. Third-generation antiepileptic drugs: Mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep. 2009;61:197-216.
  • [Malerba et al., 2010] Malerba A., Ciampa C., De Fazio S. Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy. Epilepsy Res. 2010;9:273-282.
  • [Mancl and Gidal, 2009] Mancl E.E., Gidal B.E. The effect of carbapenem antibiotics on plasma concentrations of valproic acid. Ann Pharmacother. 2009;43:2082-2087.
  • [May and Rambeck, 1985] May T.W., Rambeck B. Serum concentrations of valproic acid: influence of dose and comedication. Ther Drug Monit. 1985;7:387-390.
  • [McDonald and Robinson, 1968] McDonald M.G., Robinson D.S. Clinical observations of possible barbiturate interference with anticoagulation. J Am Med Ass. 1968;204:95-99.
  • [McCormack and Robinson, 2009] McCormack P.L., Robinson D.M. Eslicarbazepine acetate. CNS Drugs. 2009;23:71-79.
  • [Meltzer et al., 2011] Meltzer H.Y., Bonaccorso S., Bobo W.V. A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: Influence of valproic acid augmentation. J Clin Psychiatry. 2011;72:1602-1610.
  • [Messenheimer, 1998] Messenheimer J.A. Rash in adult and pediatric patients treated with lamotrigine. Can J Neurol Sci. 1998;25:S14-S18.
  • [Miceli et al., 2000] Miceli J.J., Anziano R.J., Robarge L. The effect of carbamzepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol. 2000;49:65S-70S.
  • [Michelucci et al., 1996] Michelucci R., Cipolla G., Passarelli D. Reduced plasma nisoldipine concentrations in phenytoin-treated patients with epilepsy. Epilepsia. 1996;37:1107-1110.
  • [Migliardi et al., 2007] Migliardi G., D’Arrigo C., Santoro V. Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders. Clin Neuropharmacol. 2007;30:107-113.
  • [Miller, 1991] Miller D.D. Effect of phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry. 1991;52:23-25.
  • [Mori et al., 2007] Mori H., Takahashi K., Mizutani T. Interaction between valproic acid and carbapenem antibiotics. Drug Metab Rev. 2007;39:647-657.
  • [Muscatello et al., 2005] Muscatello M.R., Pacetti M., Cacciola M. Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine. Epilepsia. 2005;46:771-774.
  • [Nawishy et al., 1981] Nawishy S., Hathaway N., Turner P. Interaction of anticonvulsant drugs with mianserin and nomifensine. Lancet. 1981;2:870-871.
  • [Nelson et al., 2001] Nelson M.H., Birnbaum A.K., Remmel R.P. Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors. Epilepsy Res. 2001;44:71-82.
  • [Nivoli et al., 2012] Nivoli A.M., Murru A., Goikolea J.M. New treatment guidelines for acute bipolar mania: A critical review. J Affect Disord. 2012;140:125-141.
  • [Nutescu et al., 2011] Nutescu E., Chuatrisorn I., Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: An update. J Thromb Thrombolysis. 2011;31:326-343.
  • [O’Brien and Guillebaud, 2010] O’Brien M.D., Guillebaud J. Contraception for women taking antiepileptic drugs. J Fam Plann Reprod Health Care. 2010;36:239-242.
  • [Oberndorfer et al., 2005] Oberndorfer S., Piribauer M., Marosi C. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol. 2005;72:255-260.
  • [Okulicz et al., 2011] Okulicz J.F., Grandits G.A., French J.A. Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: A retrospective case control study. AIDS Res Ther. 2011;8:18. Infectious Disease Clinical Research Program (IDCRP) HIV Working Group
  • [Okulicz et al., 2013] Okulicz J.F., Grandits G.A., French J.A. The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: A case-control study. Epilepsy Res. 2013;103:245-253.
  • [Olesen and Linnet, 1999] Olesen O.V., Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: The influence of comedication. Ther Drug Monit. 1999;21:87-90.
  • [Ono et al., 2002] Ono S., Mihara K., Suzuki A. Significant pharmacokinetic interaction between risperidone and carbamazepine: Its relationship with CYP2D6 genotypes. Psychopharmacology. 2002;162:50-54.
  • [Park et al., 2012] Park M.K., Lim K.S., Kim T.E. Reduced valproic acid serum concentrations due to drug interactions with carbapenem antibiotics: Overview of 6 cases. Ther Drug Monit. 2012;34:599-603.
  • [Patsalos et al., 2002] Patsalos P.N., Fröscher W., Pisani F., van Rijn C.M. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002;43:365-385.
  • [Patsalos and Perucca, 2003a] Patsalos P.N., Perucca E. Clinically important drug interactions in epilepsy: General features and interactions between antiepileptic drugs. Lancet Neurol. 2003;2:347-356.
  • [Patsalos and Perucca, 2003b] Patsalos P.N., Perucca E. Clinically important drug interactions in epilepsy: Interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2:473-481.
  • [Patsalos, 2013a] Patsalos P.N. Drug interactions with the newer antiepileptic drugs (AEDs) - Part 1: Pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet. 2013;52:927-966.
  • [Patsalos, 2013b] Patsalos P.N. Drug interactions with the newer antiepileptic drugs (AEDs) - Part 2: Pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders. Clin Pharmacokinet. 2013;52:1045-1061.
  • [Pauwels, 2002] Pauwels O. Factors contributing to carbamazepine macrolide interactions. Pharmacol Res. 2002;45:291-298.
  • [Penttila et al., 1974] Penttila O., Neuvonen P.J., Aho K., Lehtovaara R. Interaction between doxycycline and some antiepileptic drugs. BMJ. 1974;2:470-472.
  • [Perucca, 1982] Perucca E. Pharmacokinetic interactions with antiepileptic drugs. Clin Pharmacokinet. 1982;7:57-84.
  • [Perucca, 2006] Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61:246-255.
  • [Perucca, 2011] Perucca E. The pharmacology of new antiepileptic drugs: Does a novel mechanism of action really matter?. CNS Drugs. 2011;25:07-12.
  • [Perucca, 2013] Perucca E. Optimizing antiepileptic drug treatment in tumoral epilepsy. Epilepsia. 2013;54:97-104. Suppl 9
  • [Perucca and Kwan, 2005] Perucca E., Kwan P. Overtreatment in epilepsy: How it occurs and how it can be avoided. CNS Drugs. 2005;19:897-908.
  • [Perucca et al., 2008] Perucca E., Cloyd J., Critchley D., Fuseau E. Rufinamide: Clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008;49:1123-1141.
  • [Pihlsgård and Eliasson, 2002] Pihlsgård M., Eliasson E. Significant reduction of sertraline plasma levels by carbamazepine and phenytoin. Eur J Clin Pharmacol. 2002;57:915-916.
  • [Predaxa, 2014] Predaxa, Summary of Product Characteristics. http://www.medicines.org.uk/emc/medicine/20760#INTERACTIONS (last accessed April 29, 2014).
  • [Ragueneau-Majlessi et al., 2001] Ragueneau-Majlessi I., Levy R.H., Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res. 2001;47:55-63.
  • [Raitasuo et al., 1994] Raitasuo V., Lehtovaara R., Huttonen M.O. Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. Psychopharmacology. 1994;116:115-116.
  • [Rambeck and Wolf, 1993] Rambeck B., Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet. 1993;25:433-443.
  • [Reddy, 2010] Reddy D.S. Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives. Expert Rev Clin Pharmacol. 2010;3:183-192.
  • [Reidenberg et al., 1995] Reidenberg P., Glue P., Banfield C.R. Effects of felbamate on the pharmacokinetics of phenobarbital. Clin Pharmacol Ther. 1995;58:279-287.
  • [Reimers et al., 2005] Reimers A., Skogvoll E., Sund J.K., Spigset O. Drug interactions between lamotrigine and psychoactive drugs: Evidence from a therapeutic drug monitoring service. J Clin Psychopharmacol. 2005;25:342-348.
  • [Reimers et al., 2005] Reimers A., Helde G., Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia. 2005;46:1414-1417.
  • [Riegelman et al., 1970] Riegelman S., Rowland M., Epstein W.L. Griseofulvin phenobarbital interaction in man. J Amer Med Assoc. 1970;213:426-431.
  • [Riva et al., 1985] Riva R., Contin M., Albani F. Lateral gaze nystagmus in carbamazepine-treated epileptic patients: correlation with total and free plasma concentrations of parent drug and its 10,11-epoxide metabolite. Ther Drug Monit. 1985;7:277-282.
  • [Rivers et al., 2008] Rivers F., O’Brien T.J., Callaghan R. Exploring the possible interaction between anti-epilepsy drugs and multidrug efflux pumps; observations. Eur J Pharmacol. 2008;598:1-8. in vitro
  • [Sabers et al., 2001] Sabers A., Buchholt J.M., Uldall P., Hansen E.L. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res. 2001;47:151-154.
  • [Sabers et al., 2003] Sabers A., Ohman I., Christensen J., Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology. 2003;61:570-571.
  • [Sachdeo et al., 1999] Sachdeo R., Wagner M.L., Sachdeo S. Coadministration of phenytoin and felbamate: Evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate. Epilepsia. 1999;40:1122-1128.
  • [Sälke-Kellermann et al., 1997] Sälke-Kellermann R.A., May T., Boenigk H.E. Influence of ethosuximide on valproic acid serum concentrations. Epilepsy Res. 1997;26:345-349.
  • [Sake et al., 2010] Sake J.K., Hebert D., Isojärvi J., Doty P. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs. 2010;24:1055-1068.
  • [Santucci et al., 2010] Santucci R., Fothergill H., Laugel V. The onset of acute oxcarbazepine toxicity related to prescription of clarithromycin in a child with refractory epilepsy. Br J Clin Pharmacol. 2010;69:314-316.
  • [Sidhu et al., 2006a] Sidhu J., Job S., Singh S., Philipson R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol. 2006;61:191-199.
  • [Sidhu et al., 2006b] Sidhu J., Job S., Bullman J., Francis E. Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects. Br J Clin Pharmacol. 2006;61:420-426.
  • [Sitsen et al., 2001] Sitsen J., Maris F., Timmer C. Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects. Eur J Drug Metab Pharmacokinet. 2001;26:109-121.
  • [Spaans et al., 2002] Spaans E., van den Heuvel M.W., Schnabel P.G. Concomitant use of mirtazapine and phenytoin: A drug-drug interaction study in healthy male subjects. Eur J Clin Pharmacol. 2002;58:423-429.
  • [Spina and Perucca, 2002] Spina E., Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia. 2002;43:37-44. Suppl. 2
  • [Spina et al., 2000] Spina E., Avenoso A., Facciola G. Plasma concentrations of risperidone and 9-hydroxyrisperidone effect of comedication with carbamazepine or valproate. Ther Drug Monit. 2000;22:481-485.
  • [Spina et al., 2006] Spina E., D’Arrigo C., Migliardi G. Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Ther Drug Monit. 2006;28:599-602.
  • [Spina et al., 2009] Spina E., D’Arrigo C., Santoro V. Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder. Ther Drug Monit. 2009;31:758-763.
  • [Stephen, 2003] Stephen L.J. Drug treatment of epilepsy in elderly people: Focus on valproic acid. Drugs Aging. 2003;20:141-152.
  • [Tartara et al., 1991] Tartara A., Galimberti C.A., Manni R. Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine bioavailability in epileptic patients. Br J Clin Pharmacol. 1991;32:335-340.
  • [Tiihonen et al., 2003] Tiihonen J., Hallikainen T., Ryynanen O.P. Lamotrigine in treatment-resistant schizophrenia: A randomized placebo-controlled crossover trial. Biol Psychiatry. 2003;54:1241-1248.
  • [Tiihonen et al., 1995] Tiihonen J., Vartiainen H., Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry. 1995;28:26-28.
  • [Tisdel et al., 1994] Tisdel K.A., Israel D.S., Kolb K.W. Warfarin-felbamate interaction. First report. Ann Pharmacother. 1994;28:805.
  • [Tompson and Crean, 2014] Tompson D.J., Crean C.S. The interaction potential of retigabine (ezogabine) with other antiepileptic drugs. Curr Clin Pharmacol. 2014;9:148-156.
  • [Tomson and Hiilesmaa, 2007] Tomson T., Hiilesmaa V. Epilepsy in pregnancy. BMJ. 2007;335:769-773.
  • [Topamax, 2014] Topamax. Summary of Product Characteristics, Janssen-Cilag Limited, High Wycombe, Bucks (http://www.medicines.org.uk/emc/medicine/6768#INTERACTIONS (accessed April 29, 2014).
  • [Tothfalusi et al., 2008] Tothfalusi L., Speidl S., Endrenyi L. Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets. Br J Clin Pharmacol. 2008;65:110-122.
  • [Tran et al., 1996] Tran A., Vauzelle-Kervroedan F., Rey E. Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children. Eur J Clin Pharmacol. 1996;50:497-500.
  • [Trojnar et al., 2005] Trojnar M.K., Wojtal K., Trojnar M.P., Czuczwar S.J. Stiripentol. A novel antiepileptic drug. Pharmacol Rep. 2005;57:154-160.
  • [Tsiropoulos et al., 2006] Tsiropoulos I., Gichangi A., Andersen M. Trends in utilization of antiepileptic drugs in Denmark. Acta Neurol Scand. 2006;113:405-411.
  • [Tucker et al., 1992] Tucker R.M., Denning D.W., Hanson L.H. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis. 1992;14:165-174.
  • [Valsalan and Cooper, 1982] Valsalan V.C., Cooper G.L. Carbamazepine intoxication caused by interaction with isoniazid. BMJ. 1982;285:261-262.
  • [Vandel et al., 1988] Vandel S., Bertschy G., Jounet J.M. Valpromide increases the plasma concentrations of amitriptyline and its metabolite nortriptyline in depressive patients. Ther Drug Monit. 1988;10:386-389.
  • [Vander Lee et al., 2006] Vander Lee M.J., Dawood L., ter Hofstede H.J. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther. 2006;80:159-168.
  • [Vaz-da-Silva et al., 2010] Vaz-da-Silva M., Almeida L., Falcão A. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study. Clin Ther. 2010;32:179-192.
  • [Vecht et al., 2003] Vecht C.J., Wagner G.L., Wilms E.B. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol. 2003;2:404-409.
  • [Wagner et al., 1991] Wagner M.L., Graves N.M., Marienau K. Discontinuation of phenytoin and carbamazepine in patients receiving felbamate. Epilepsia. 1991;32:398-406.
  • [Wagner et al., 1994] Wagner M.L., Graves N.M., Leppik I.E. The effect of felbamate on valproic acid disposition. Clin Pharmacol Ther. 1994;56:494-502.
  • [Walzer et al., 2012] Walzer M., Bekersky I., Blum R.A., Tolbert D. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome p450 isoenzymes. Pharmacotherapy. 2012;32:340-353.
  • [Weller et al., 2011] Weller M., Gorlia T., Cairncross J.G. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 2011;77:1156-1164.
  • [Winter et al., 2007] Winter H.R., DeVane C.L., Figueroa C. Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Hum Psychopharmacol Clin Exp. 2007;22:469-476.
  • [Wong et al., 1996] Wong S.L., Cavanaugh J., Shi H. Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Clin Pharmacol Ther. 1996;60:48-53.
  • [Wong et al., 2001] Wong Y.W., Yeh C., Thyrum P.T. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol. 2001;21:89-93.
  • [Wong et al., 2006] Wong J.O., Leung S.P., Mak T. Plasma clozapine levels and clinical response in treatment refractory Chinese schizophrenic patients. Prog Neuro-Psychopharmacol Biol Psychiatry. 2006;30:251-264.
  • [Worden et al., 1984] Worden J.P. Jr., Wood C.A. Jr., Workman C.H. Phenytoin and nasogastric feedings. Neurology. 1984;34:132.
  • [Xarelto, 2014] Xarelto. Summary of Product Characteristics https://www.medicines.org.uk/emc/medicine/25586/SPC/Xarelto+20mg+film-coated+tablets/#INTERACTIONS (last accessed April 29, 2014).
  • [Yagi et al., 2012] Yagi T., Naito T., Mino Y. Impact of concomitant antacid administration on gabapentin plasma exposure and oral bioavailability in healthy adult subjects. Drug Metab Pharmacokinet. 2012;27:248-254.
  • [Yamamoto et al., 2014] Yamamoto Y., Takahashi Y., Imai K. Interaction between sulthiame and clobazam: Sulthiame inhibits the metabolism of clobazam, possibly via an action on CYP2C19. Epilepsy Behav. 2014;34:124-126.
  • [Yoon et al., 2011] Yoon H.W., Giraldo E.A., Wijdicks E.F. Valproic acid and warfarin: an underrecognized drug interaction. Neurocrit Care. 2011;15:182-185.
  • [Yuen et al., 1992] Yuen A.W.C., Land G., Weatherley B., Peck A.W. Sodium valproate inhibits lamotrigine metabolism. Br J Clin Pharmacol. 1992;33:511-513.
  • [Zaccara et al., 2004] Zaccara G., Cincotta M., Borgheresi A., Balestrieri F. Adverse motor effects induced by antiepileptic drugs. Epileptic Disord. 2004;6:153-168.
  • [Zaccara et al., 2012] Zaccara G., Perucca P., Gangemi P.F. The adverse event profile of pregabalin across different disorders: A meta-analysis. Eur J Clin Pharmacol. 2012;68:903-912.
  • [Zaccara et al., 2013] Zaccara G., Giovannelli F., Cincotta M., Iudice A. AMPA receptor inhibitors for the treatment of epilepsy: The role of perampanel. Expert Rev Neurother. 2013;13:647-655.
  • [Zhou et al., 2007] Zhou S.F., Xue C.C., Yu X.Q., Li C., Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29:687-710.